BR112019004877A2 - novos compostos e usos terapêuticos dos mesmos - Google Patents
novos compostos e usos terapêuticos dos mesmosInfo
- Publication number
- BR112019004877A2 BR112019004877A2 BR112019004877A BR112019004877A BR112019004877A2 BR 112019004877 A2 BR112019004877 A2 BR 112019004877A2 BR 112019004877 A BR112019004877 A BR 112019004877A BR 112019004877 A BR112019004877 A BR 112019004877A BR 112019004877 A2 BR112019004877 A2 BR 112019004877A2
- Authority
- BR
- Brazil
- Prior art keywords
- new compounds
- therapeutic uses
- compounds
- pathogen
- bind
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615560.8A GB201615560D0 (en) | 2016-09-13 | 2016-09-13 | Novel compounds and therapeutic uses thereof |
| GBGB1707076.4A GB201707076D0 (en) | 2017-05-04 | 2017-05-04 | Novel compounds and therapeutic uses thereof |
| PCT/GB2017/052699 WO2018051085A1 (en) | 2016-09-13 | 2017-09-13 | Novel compounds and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019004877A2 true BR112019004877A2 (pt) | 2019-06-11 |
Family
ID=59923474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019004877A BR112019004877A2 (pt) | 2016-09-13 | 2017-09-13 | novos compostos e usos terapêuticos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11014966B2 (https=) |
| EP (1) | EP3512544B1 (https=) |
| JP (2) | JP7185622B2 (https=) |
| KR (1) | KR102544465B1 (https=) |
| CN (1) | CN110022896B (https=) |
| AU (1) | AU2017328896B2 (https=) |
| BR (1) | BR112019004877A2 (https=) |
| DK (1) | DK3512544T3 (https=) |
| ES (1) | ES2854991T3 (https=) |
| IL (1) | IL265269B (https=) |
| MX (1) | MX2019002879A (https=) |
| WO (1) | WO2018051085A1 (https=) |
| ZA (1) | ZA201901422B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201705686D0 (en) * | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201804098D0 (en) * | 2018-03-14 | 2018-04-25 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| GB201904534D0 (en) * | 2019-04-01 | 2019-05-15 | Centauri Therapeutics Ltd | Novel compounds an therapeutic uses thereof |
| GB202406865D0 (en) | 2024-05-15 | 2024-06-26 | Centauri Therapeutics Ltd | Novel compounds and therapeutics uses thereof |
| WO2025236916A1 (en) * | 2024-05-16 | 2025-11-20 | Brii Biosciences, Inc. | Compositions and methods for treating infections |
| GB202410052D0 (en) * | 2024-07-10 | 2024-08-21 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| EP1594898A2 (en) * | 2003-02-06 | 2005-11-16 | Tripep AB | Glycosylated specificity exchangers |
| CA2517396A1 (en) * | 2003-02-28 | 2005-03-10 | Antigenics Inc. | Use of lectins to promote oligomerization of glycoproteins and antigenic molecules |
| BRPI1011269A2 (pt) * | 2009-05-05 | 2016-09-27 | Altermune Technologies Llc | imunidade quimicamente programável |
| CA2855916A1 (en) * | 2011-11-18 | 2013-05-23 | Novacta Biosystems Limited | Polymyxin derivatives |
| WO2016104647A1 (ja) | 2014-12-25 | 2016-06-30 | 国立大学法人大阪大学 | 糖鎖結合ワクチン抗原及び糖鎖導入剤 |
| GB201517859D0 (en) | 2015-10-08 | 2015-11-25 | Altermune Ltd | Novel compounds and therapeutic uses thereof |
-
2017
- 2017-09-13 WO PCT/GB2017/052699 patent/WO2018051085A1/en not_active Ceased
- 2017-09-13 DK DK17771531.5T patent/DK3512544T3/da active
- 2017-09-13 ES ES17771531T patent/ES2854991T3/es active Active
- 2017-09-13 EP EP17771531.5A patent/EP3512544B1/en active Active
- 2017-09-13 BR BR112019004877A patent/BR112019004877A2/pt unknown
- 2017-09-13 KR KR1020197010569A patent/KR102544465B1/ko active Active
- 2017-09-13 JP JP2019513946A patent/JP7185622B2/ja active Active
- 2017-09-13 US US16/333,219 patent/US11014966B2/en active Active
- 2017-09-13 AU AU2017328896A patent/AU2017328896B2/en active Active
- 2017-09-13 MX MX2019002879A patent/MX2019002879A/es unknown
- 2017-09-13 CN CN201780069622.1A patent/CN110022896B/zh active Active
-
2019
- 2019-03-07 ZA ZA201901422A patent/ZA201901422B/en unknown
- 2019-03-11 IL IL265269A patent/IL265269B/en unknown
-
2022
- 2022-09-09 JP JP2022143727A patent/JP2022184922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11014966B2 (en) | 2021-05-25 |
| EP3512544A1 (en) | 2019-07-24 |
| EP3512544B1 (en) | 2020-10-28 |
| KR20190064592A (ko) | 2019-06-10 |
| AU2017328896B2 (en) | 2024-07-25 |
| US20190248838A1 (en) | 2019-08-15 |
| JP2022184922A (ja) | 2022-12-13 |
| NZ751662A (en) | 2025-05-02 |
| JP7185622B2 (ja) | 2022-12-07 |
| ES2854991T3 (es) | 2021-09-23 |
| MX2019002879A (es) | 2019-09-18 |
| KR102544465B1 (ko) | 2023-06-19 |
| JP2019526614A (ja) | 2019-09-19 |
| CN110022896A (zh) | 2019-07-16 |
| WO2018051085A1 (en) | 2018-03-22 |
| CA3036405A1 (en) | 2018-03-22 |
| CN110022896B (zh) | 2023-12-19 |
| IL265269B (en) | 2022-04-01 |
| IL265269A (en) | 2019-05-30 |
| AU2017328896A1 (en) | 2019-04-04 |
| DK3512544T3 (da) | 2021-02-01 |
| ZA201901422B (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019004877A2 (pt) | novos compostos e usos terapêuticos dos mesmos | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| EA201991207A1 (ru) | Новые агонисты tnfr и их применение | |
| BR112018000632A2 (pt) | moléculas de anticorpo que ligam a cd79 | |
| BR112017016417A2 (pt) | moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos | |
| JOP20200110B1 (ar) | إينانشيوميرات من الثيازولات المستبدلة كمركبات مضادة للفيروسات | |
| BR112018073676A2 (pt) | lipossomas peguilados e métodos de uso | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112018000604A2 (pt) | moléculas de anticorpo que ligam cd45 | |
| BR112017009545B8 (pt) | Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112016029906A2 (pt) | compostos excipientes redutores de viscosidade para formulações proteicas | |
| BR112015026830A8 (pt) | composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112015030229A8 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| BR112016020377A2 (pt) | proteínas fc multiméricas | |
| JOP20180026A1 (ar) | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
| MX2017010628A (es) | Proteinas especificas novedosas para pioverdina y pioquelina. | |
| BR112016011866A2 (pt) | vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112017002173A2 (pt) | anticorpos semelhantes à angiopoietina e métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |